Compare IMNM & MAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMNM | MAN |
|---|---|---|
| Founded | 2006 | 1948 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.5B |
| IPO Year | 2020 | 1994 |
| Metric | IMNM | MAN |
|---|---|---|
| Price | $18.76 | $46.57 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 17 | 12 |
| Target Price | $35.13 | ★ $51.94 |
| AVG Volume (30 Days) | ★ 1.4M | 893.7K |
| Earning Date | 11-09-2026 | 10-15-2026 |
| Dividend Yield | N/A | ★ 3.13% |
| EPS Growth | ★ 51.40 | N/A |
| EPS | N/A | ★ 1.89 |
| Revenue | $6,941,000.00 | ★ $17,957,100,000.00 |
| Revenue This Year | N/A | $6.51 |
| Revenue Next Year | N/A | $3.29 |
| P/E Ratio | ★ N/A | $24.34 |
| Revenue Growth | N/A | ★ 0.58 |
| 52 Week Low | $16.41 | $25.15 |
| 52 Week High | $30.06 | $63.88 |
| Indicator | IMNM | MAN |
|---|---|---|
| Relative Strength Index (RSI) | 46.46 | 45.57 |
| Support Level | $17.18 | $44.02 |
| Resistance Level | $23.30 | $48.48 |
| Average True Range (ATR) | 1.39 | 1.57 |
| MACD | 0.20 | 0.43 |
| Stochastic Oscillator | 25.98 | 64.13 |
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
ManpowerGroup Inc provides workforce solutions and services, including recruitment and assessment, upskilling, reskilling, training and development, career management, outsourcing, and workforce consulting. The company leverages its trusted brands, industry knowledge, and AI-enabled assessments and offers an extensive portfolio of training and leadership development solutions. Its reportable segments are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others, with Staffing and Interim generating the majority of revenue. It operates in the Americas, Southern Europe, Northern Europe, and APME. The company derives the maximum geographical revenue from the Southern European region.